Nvidia bets on agentic AI to turbocharge biotech discovery
Nvidia announced its focus on agentic AI at the Bio International Convention in San Diego, betting on autonomous AI systems to accelerate biotech discovery. The company's push reflects the growing role of AI in the biotech industry ecosystem.
The Atomic take
Nvidia is moving beyond selling chips to positioning its AI agents as active participants in drug discovery, which deepens its hold over pharmaceutical research budgets just as it already dominates the hardware those labs depend on. The real test is whether autonomous systems can shorten validation timelines that still hinge on wet-lab experiments and regulatory review, neither of which compute power alone can speed up. Watch which biotech firms commit to building on Nvidia's agentic tools versus keeping their own models in-house.
Read the full story at SiliconANGLE News →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five